CRAT

Carnitine O-acetyltransferase · P43155 · CRAT on Sugi Atlas →

584 patent compounds predicted against CRAT, 510 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4339313	1.00	1/20
SCHEMBL5712374	1.00	1/20
SCHEMBL5712398	1.00	1/20
Hydrochloric Acid (SCHEMBL10415559)	0.68	1/20
Hydrochloric Acid (SCHEMBL10415560)	0.68	1/20
Hydrochloric Acid (SCHEMBL10415561)	0.68	1/20
SCHEMBL24634587	0.65	1/20
SCHEMBL14070123	0.63	1/20
SCHEMBL24634589	0.63	1/20
SCHEMBL24634585	0.61	1/20
SCHEMBL24634586	0.59	1/20
SCHEMBL3679267	0.58	1/20
SCHEMBL3679268	0.58	1/20
Hydrochloric Acid (SCHEMBL10636958)	0.58	1/20
SCHEMBL10414822	0.58	1/20
SCHEMBL10414824	0.58	1/20
Palmitoylaminocarnitine (SCHEMBL10414831)	0.58	1/20
Palmitoylaminocarnitine (SCHEMBL10414832)	0.58	1/20
SCHEMBL10415637	0.58	1/20
SCHEMBL10415639	0.58	1/20

Clinical trials — most relevant to CRAT by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Identification of Carnitine-Responsive Cardiomyopathy	PHASE4	UNKNOWN
Effect of Acetyl-L-carnitine in Migraine	PHASE4	COMPLETED
Evaluation of the Effects of L-Carnitine Injection in Patients Undergoing Hemodialysis	PHASE4	UNKNOWN
Bezafibrate Trial in CPT2 Deficiency	PHASE3	UNKNOWN
Impact on Functional Status in Older Adults Treated With L-Carnitine	PHASE2/PHASE3	UNKNOWN
Acetyl-L-Carnitine Reduces Perceived Work Stress and Improves Work Ability and Work Performance in Hepatic Encephalopathy	PHASE3	COMPLETED
Impact of Hemodialysis on Plasma Carnitine Levels in Patients With End Stage Renal Disease	PHASE2/PHASE3	COMPLETED
Acetylcarnitine and Insulin Sensitivity	PHASE2	COMPLETED
Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects	PHASE2	COMPLETED
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease	PHASE2	COMPLETED
Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients	PHASE2	COMPLETED
A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients	PHASE2	COMPLETED
Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension	PHASE1	COMPLETED
Markers of Carnitine Acetyltransferase (CrAT) Protein Activity and Carnitine Availability	nan	COMPLETED
Acetylcarnitine and Metabolic Flexibility	nan	COMPLETED
Effects of Parenteral L-carnitine Supplementation in Premature Neonates	nan	COMPLETED
Systemic Biomarkers of Brain Injury From Hyperammonemia	nan	RECRUITING
The Analysis of Fatigue on Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia	nan	UNKNOWN
Investigating the Gut Microbiota Modulation Effects of Allicin for Cardiovascular Disease Protection and Establishing Microbiota Directed Personalized Nutrition Guidance With Novel Humanized Gnotobiotic Mice Model, Microbial Culturomics and Metabolomic Technique	nan	COMPLETED
Influence of OCTN2 Variants on Carnitine Status and Plasma Triglycerides	nan	COMPLETED
KETO-TUMOR: a Study on Brain Tumors and Central Obesity	nan	RECRUITING
Compassionate Use of Triheptanoin (C7) for Inherited Disorders of Energy Metabolism	nan	NO_LONGER_AVAILABLE
A Prospective Study of the Disease Characteristics of Adult Patients With Long Chain Fatty Acid Oxidation Disorders	nan	COMPLETED
Lactate Profile and Fat Oxidation During Exercise	nan	COMPLETED
Nutritional Therapy of the Deficits of Oxidation Mitochondrial of the Fatty Acids	nan	COMPLETED
Influence of WNT4 VEZT FSHB and SIRT1 SNPs in Endometriosis: a Case Control Study of the Sardinian Population	nan	UNKNOWN
Nephroprotective Effects of Carnitine and (PDE5) Inhibitor Agent Against Contrast Media-induced Nephropathy (CMN)	nan	UNKNOWN
Using Gut Microbial Gbu Gene Testing to Estimate Host TMAO Production Capacity	nan	ACTIVE_NOT_RECRUITING
The Ketogenic Diet in the Treatment of Alzheimer's Disease	nan	COMPLETED
The Ketogenic Diet in the Treatment of Behavioral Variant Frontotemporal Dementia	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a CRAT binder may also engage these)

Protein	Name	Similarity
Q704S8	—	1.000	Q704S8 →
P47934	—	1.000	P47934 →
P52826	—	1.000	P52826 →
O19094	—	0.994	O19094 →
P11466	—	0.993	P11466 →
P32738	—	0.993	P32738 →
B2ZGJ1	—	0.992	B2ZGJ1 →
Q03059	—	0.992	Q03059 →
Q90YJ9	—	0.990	Q90YJ9 →
P18886	—	0.990	P18886 →
Q9UKG9	—	0.990	Q9UKG9 →
Q9DC50	—	0.989	Q9DC50 →
CPT2	Carnitine O-palmitoyltransferase 2, mitochondrial	0.988	landscape →
Q2KJB7	—	0.988	Q2KJB7 →
P13222	—	0.988	P13222 →
Q63704	—	0.986	Q63704 →
Q60HG9	—	0.986	Q60HG9 →
Q7ZXE1	—	0.986	Q7ZXE1 →
P52825	—	0.985	P52825 →
Q5U3U3	—	0.984	Q5U3U3 →
Q924X2	—	0.984	Q924X2 →
Q8HY46	—	0.983	Q8HY46 →
Q6P4X5	—	0.982	Q6P4X5 →
CPT1A	Carnitine O-palmitoyltransferase 1, liver isoform	0.982	landscape →
CPT1B	Carnitine O-palmitoyltransferase 1, muscle isoform	0.979	landscape →
P32198	—	0.979	P32198 →
CHAT	Choline O-acetyltransferase	0.979	landscape →
P07668	—	0.978	P07668 →
Q58DK1	—	0.978	Q58DK1 →
Q68Y62	—	0.978	Q68Y62 →